menu
    • menu
    [{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"177-Lu BetaBart","moa":"CD276","graph1":"Oncology","graph2":"IND Enabling","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radiopharm Theranostics \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"5","companyTruncated":"Radiopharm Theranostics \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"Betabart","moa":"CD276","graph1":"Oncology","graph2":"IND Enabling","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radiopharm Theranostics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Radiopharm Theranostics \/ Undisclosed"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"177-Lu RAD202","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Radiopharm Theranostics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Radiopharm Theranostics \/ Undisclosed"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"177-Lu RAD202","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Radiopharm Theranostics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Radiopharm Theranostics \/ Undisclosed"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"177-Lu RAD202","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Radiopharm Theranostics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Radiopharm Theranostics \/ Undisclosed"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Cyclotek","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2025","type":"Agreement","leadProduct":"161-Tb RAD 402","moa":"KLK3","graph1":"Oncology","graph2":"Preclinical","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radiopharm Theranostics \/ Cyclotek","highestDevelopmentStatusID":"4","companyTruncated":"Radiopharm Theranostics \/ Cyclotek"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"RAD204","moa":"PDL1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radiopharm Theranostics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Radiopharm Theranostics \/ Undisclosed"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Isotope Technologies Munich","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabeled Compound","year":"2025","type":"Agreement","leadProduct":"177-Lu RAD204","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Radiopharm Theranostics \/ Radiopharm Theranostics","highestDevelopmentStatusID":"6","companyTruncated":"Radiopharm Theranostics \/ Radiopharm Theranostics"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"177-Lu RAD204","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Radiopharm Theranostics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Radiopharm Theranostics \/ Undisclosed"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"177-Lu RAD204","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radiopharm Theranostics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Radiopharm Theranostics \/ Undisclosed"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"TerThera","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Radiolabeled Compound","year":"2023","type":"Agreement","leadProduct":"RAD602","moa":"PTPRM","graph1":"Oncology","graph2":"Preclinical","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Radiopharm Theranostics \/ Radiopharm Theranostics","highestDevelopmentStatusID":"4","companyTruncated":"Radiopharm Theranostics \/ Radiopharm Theranostics"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"18-F FPIA","moa":"Pyruvate kinase","graph1":"Oncology","graph2":"Phase II","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Radiopharm Theranostics \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Radiopharm Theranostics \/ Medpace, Inc"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"68-Ga RAD301","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Radiopharm Theranostics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Radiopharm Theranostics \/ Undisclosed"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"68-Ga Trivehexin","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Radiopharm Theranostics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Radiopharm Theranostics \/ Undisclosed"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Lantheus Holding","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2024","type":"Private Placement","leadProduct":"68-Ga Trivehexin","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Radiopharm Theranostics","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Radiopharm Theranostics \/ Lantheus Holding","highestDevelopmentStatusID":"6","companyTruncated":"Radiopharm Theranostics \/ Lantheus Holding"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"SHINE Technologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"n.c.a. 177-Lu","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radiopharm Theranostics \/ SHINE Technologies","highestDevelopmentStatusID":"4","companyTruncated":"Radiopharm Theranostics \/ SHINE Technologies"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"TerThera","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"RAD 402","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radiopharm Theranostics \/ Radiopharm Theranostics","highestDevelopmentStatusID":"4","companyTruncated":"Radiopharm Theranostics \/ Radiopharm Theranostics"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Pharma15","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radiopharm Theranostics \/ Radiopharm Theranostics","highestDevelopmentStatusID":"4","companyTruncated":"Radiopharm Theranostics \/ Radiopharm Theranostics"}]

    Find Clinical Drug Pipeline Developments & Deals by Radiopharm Theranostics

    Menu

    Radiopharm Theranostics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Radiopharm Theranostics

                            Australia arrow
                            Organic Process R&D
                            Not Confirmed

                            Radiopharm Theranostics

                            Australia arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Betabart

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Clears Radiopharm IND For Betabart (RV-01) Phase I Targeting B7H3

                            Details : RV-01 (betabart), its Lu177-B7H3 monoclonal antibody designed with strong affinity for the 4Ig isoform of B7H3 that is highly expressed in tumors and not in healthy tissues.

                            Product Name : RV-01

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            July 28, 2025

                            Lead Product(s) : Betabart

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Radiopharm Theranostics

                            Australia arrow
                            Organic Process R&D
                            Not Confirmed

                            Radiopharm Theranostics

                            Australia arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 161-Tb RAD 402

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Cyclotek

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Radiopharm and Cyclotek Sign Clinical Supply Agreement for ¹⁶¹Tb-KLK3-mAb

                            Details : The agreement aims to supply radiolabel RAD 402, an anti-KLK3 monoclonal antibody, with Terbium-161 (161Tb) in Australia, which supports the initiation of a Phase 1 clinical trial.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Undisclosed

                            June 24, 2025

                            Lead Product(s) : 161-Tb RAD 402

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Cyclotek

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Radiopharm Theranostics

                            Australia arrow
                            Organic Process R&D
                            Not Confirmed

                            Radiopharm Theranostics

                            Australia arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu BetaBart

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : The University of Texas MD Anderson Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Radiopharm Shows Lu177-B7H3-mAb with Favourable Biodistribution, High Tumour Uptake

                            Details : RV01 is the Company’s B7-H3-targeted radiopharmaceutical therapy designed with strong affinity for the 4Ig isoform of B7H3.

                            Product Name : RV01

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            June 02, 2025

                            Lead Product(s) : 177-Lu BetaBart

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : The University of Texas MD Anderson Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Radiopharm Theranostics

                            Australia arrow
                            Organic Process R&D
                            Not Confirmed

                            Radiopharm Theranostics

                            Australia arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu RAD204

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Isotope Technologies Munich

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177

                            Details : Radiopharm will use ITM’s n.c.a. 177Lu across its clinical pipeline, including in key programs such as RAD 204, RAD 202, and RV01, for the treatment of solid tumors.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Undisclosed

                            May 19, 2025

                            Lead Product(s) : 177-Lu RAD204

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Isotope Technologies Munich

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Radiopharm Theranostics

                            Australia arrow
                            Organic Process R&D
                            Not Confirmed

                            Radiopharm Theranostics

                            Australia arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu RAD204

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Radiopharm Speeds 177Lu-RAD204 Trial After DSMC Gives Positive Go-Ahead

                            Details : 177Lu-RAD204 is a PD-L1 modulator radiolabelled antibody, which is being evaluated for the treatment of PD-L1 positive advanced cancers.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            May 12, 2025

                            Lead Product(s) : 177-Lu RAD204

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Radiopharm Theranostics

                            Australia arrow
                            Organic Process R&D
                            Not Confirmed

                            Radiopharm Theranostics

                            Australia arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu RAD202

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            New RAD202 Data Confirms Positive Tumor Uptake and Favorable Biodistribution

                            Details : RAD202 is a proprietary single domain antibody that targets HER2. It is being investigated for the treatment of HER2-positive solid tumors.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            March 17, 2025

                            Lead Product(s) : 177-Lu RAD202

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Radiopharm Theranostics

                            Australia arrow
                            Organic Process R&D
                            Not Confirmed

                            Radiopharm Theranostics

                            Australia arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu RAD202

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HEAT Trial (HER2 Antibody Therapy With Lutetium-177)

                            Details : 177-Lu RAD202 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            February 13, 2025

                            Lead Product(s) : 177-Lu RAD202

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Radiopharm Theranostics

                            Australia arrow
                            Organic Process R&D
                            Not Confirmed

                            Radiopharm Theranostics

                            Australia arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 18-F FPIA

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Medpace, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases

                            Details : 18-F FPIA is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neoplasm Metastasis.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            January 15, 2025

                            Lead Product(s) : 18-F FPIA

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Medpace, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Radiopharm Theranostics

                            Australia arrow
                            Organic Process R&D
                            Not Confirmed

                            Radiopharm Theranostics

                            Australia arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu RAD202

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial

                            Details : 177Lu-RAD202 is an HER2 inhibitor, antibody radiopharmaceutical candiidate, which is being evaluated for the treatment of HER2-expressing solid tumors.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            December 20, 2024

                            Lead Product(s) : 177-Lu RAD202

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Radiopharm Theranostics

                            Australia arrow
                            Organic Process R&D
                            Not Confirmed

                            Radiopharm Theranostics

                            Australia arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 68-Ga Trivehexin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Lantheus Holding

                            Deal Size : $18.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Radiopharm Receives Strategic Investment for up to A$18 million

                            Details : The company will use the net proceeds of Lantheus’ investment for drug advancement RAD301 ([68Ga]-Trivehexin), which is being evaluated for treating pancreatic neoplasms.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Undisclosed

                            June 19, 2024

                            Lead Product(s) : 68-Ga Trivehexin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Lantheus Holding

                            Deal Size : $18.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth